BLOOMBERG INTELLIGENCE / SYMPHONY HEALTH SOLUTIONS
`FAQS & DATA RELEASE DATES
`CONTENTS
`
`CLICK ON A LINK BELOW TO BE TAKEN DIRECTLY TO THE SECTION:
`
`• SYMPHONY HEALTH FAQS
`• SYMPHONY HEALTH WEEKLY RETAIL PRESCRIPTION DATA RELEASES
`• SYMPHONY HEALTH MONTHLY RETAIL DATA RELEASES
`• SYMPHONY HEALTH MONTHLY INSTITUTIONAL DATA RELEASES
`• SYMPHONY HEALTH MONTHLY INTEGRATED DATA RELEASES
`• ATTRIBUTES AND METRICS
`• DISCLAIMER
`
`Return to Table of Contents
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 1
`
`

`

`SYMPHONY HEALTH SOLUTIONS INTEGRATED DATAVERSETM (IDV) - FAQS
`
`Question
`Number
`
`1
`
`Question
`
`Summary
`What is the new Integrated
`Dataverse (IDV)?
`
`
`2
`
`What changes can I expect to see
`when comparing IDV to Legacy PHAST
`data?
`
`
`How is IDV™ different than
`“Legacy”?
`
`•
`
`Integrated Dataverse™ (IDV) is the most
`comprehensive and interconnected
`source of healthcare data in the industry,
`bringing together vast claims resources –
`medical, hospital, and prescription – with
`rich point-of-sale prescription data, non-
`retail invoice data, and demographic
`data. IDV™ offers one consistent market
`view across prescriber, payer, and
`patient dimensions, answering key
`questions and facilitating critical
`commercial processes within sales,
`marketing, and managed markets.
`• Due to additional content and changes to
`methodology, Bloomberg terminal users
`can expect so see the following:
`o Reported volume for the mail
`order channel and specialty
`products may increase for
`specific brands due to the
`increase sample coverage in
`markets such as Antineoplastic &
`Immunomodulating Agents
`In general, reported volume for
`brands have declined due to
`improvements in capturing sold
`prescriptions
`Increased accuracy and
`alignment with pharma ex-
`factory sales via new
`methodology that emphasizes
`Rxs sold (vs Rxs dispensed)
`o Projected Puerto Rico data
`available as a standard offering
`with PHAST where we now
`report projected prescriptions
`written and dispensed in PR
`o More Over the Counter supplies
`within the retail channel
`(specifically in the Diabetes
`therapeutic area)
`
`o
`
`o
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 2
`
`

`

`Question
`Number
`3
`
`Question
`
`What is the difference between sold
`and dispensed prescriptions?
`
`
`4
`
`5
`
`6
`
`7
`
`
`8
`
`What is the Retail and Mail Order
`coverage in IDV?
`
`How did SHS increase its coverage in
`these channels?
`
`
`Which PHAST audit data contains the
`new IDV projected prescription data?
`
`Does PHAST Institution (NonRetail)
`data change?
`
`Volume and Sample Changes in IDV
`Why are the projected IDV volumes
`lower than Legacy?
`
`•
`
`How is IDV™ different than
`“Legacy”?
`•
`“Sold prescriptions” is the count of
`prescriptions that were purchased by a
`patient and left the pharmacy bin
`“Dispensed prescriptions” is the count of
`prescriptions that were submitted, filled
`by the pharmacy, and ready for pick up.
`This count includes prescriptions that
`may have been re-shelved if ultimately
`the patient did not make the purchase
`• 90% Retail
`• 64% Mail Order
`
`• Symphony’s significant investment in
`specialty and mail order suppliers has
`increased sample and reduced instances
`of blocked products
`• PHAST Retail Prescription Weekly and
`Monthly
`• PHAST Integrated (the retail portion only)
`• No, the sell into the non-retail
`institutions is not impacted by IDV
`
`
`• The sample size in the IDV retail and mail
`order repositories increased with the
`addition of over 8,000 retail and mail
`order pharmacies to the sample. While
`this addition allows for more robust
`inputs into the sample, projected
`volumes may be lower.
`o Projected volumes may be lower
`due to reporting of “sold” Rx’s (i.e.,
`the script was accepted by the
`patient) vs “dispensed/filled” (i.e.,
`the script was put in the bin, but
`was not sold).
`o A portion of the Rx transactions
`included in the prior data were the
`initial transaction and not the final
`‘sold’ transaction. By reflecting only
`sold volume in the projection, there
`may be differences in the final
`projected volume.
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 3
`
`

`

`Question
`Number
`
`9
`
`Question
`
`Brand Specific Changes in IDV
`Why did my Generic/Brand share
`shift?
`
`
`10
`
`Why do some brands/therapeutic
`classes have different impacts than
`others in IDV?
`
`
`11
`
`12
`
`What is the difference in TRx volume
`at the national level for IDV
`
`
`What is the difference in TRx volume at the
`national level for IDV for branded products?
`
`
`How is IDV™ different than
`“Legacy”?
`
`• Market shares and Generic/Brand rates
`will be different in IDV due to a shift in
`the mix of pharmacies in the IDV sample,
`and the reporting of final disposition of
`sold Rxs.
`o Because more “independent”
`pharmacies are captured in the IDV
`sample, the patient population and
`mix of drugs dispensed is different.
`Generally, independent pharmacies
`exhibit a higher generic drug
`dispensing rate than chain
`pharmacies in urban areas.
`o Because IDV reports the sold Rx (vs.
`dispensed Rx), generic substitution
`for branded drugs will change the
`Generic/Brand mix and/or market
`share.
`
`
`• Brands with high Abandonment/Reversal
`rates may see lower Rx volumes and
`market shares in IDV because IDV reports
`volume based on sold prescriptions vs.
`dispensed.
`• Brands and therapeutic classes that are
`more heavily dispensed through a Retail
`pharmacy may have a higher impact due
`to auto-fill practices and the frequency
`when patients don’t pick up their
`prescription.
`• Specialty brands that are dispensed
`through mail order typically have less of
`an impact because of the type of disease
`state they are treating. Patients typically
`don’t send their prescription back through
`the mail once they’ve received it.
`• For the year 2014, there is approximately
`a 2% decrease in overall Total Rx Volume,
`with the majority of volume in the Retail
`Channel and Generic product category.
`• For the year 2014, there is approximately
`a 4% decrease in overall Total Rx Volume.
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 4
`
`

`

`Question
`Number
`13
`
`14
`
`15
`
`16
`
`
`
`17
`
`Question
`
`What is the difference in TRx volume
`at the national level for IDV for
`Generic products?
`
`What is the difference in TRx volume
`at the national level for IDV for the
`top 25 Branded products?
`
`What is the difference in TRx volume
`at the national level for IDV for the
`top 25 Generic products?
`
`What is the difference in TRx volume
`at the state level for IDV?
`
`Methodology Questions
`Will the projection methodology
`change when transitioning to IDV?
`
`8
`
`What about reporting for Puerto Rico
`in IDV?
`
`
`
`How is IDV™ different than
`“Legacy”?
`• For the year 2014, there is approximately
`a 1% decrease in overall Total Rx Volume.
`
`• For the year 2014, there is approximately
`a 4% decrease in overall Total Rx Volume.
`
`• For the year 2014, there is approximately
`a 1% decrease in overall Total Rx Volume.
`
`• Changes in TRx volume across
`geographies vary slightly, yet remain
`consistent with the national average.
`
`• The IDV Sample and Universe considers
`more robust inputs derived from the
`integration of our Point of Service (POS)
`and Lifecycle claims data assets.
`o The increase in sample size and
`reporting of “observable facts”
`provides tighter confidence intervals
`for projected volumes and shares
`• The projection methodology remains the
`same in IDV:
`o 100% of projected Rx volume is
`assigned to prescribers (no zip
`default)
`o Adjusts for product specific sample
`biases by dispensing COT
`o Projection factors are calculated
`based on identical units (Rx to Rx, not
`$ to Rx)
`o Projection zones are fixed and
`aligned to account for geographic and
`socio-demographic variance
`o All Rxs are prescriber linked and
`reported as integers; there are no
`fractional Rx counts
`• The new IDV projected offering includes
`Puerto Rico Rxs.
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 5
`
`

`

`
`
`
`
`BI / SYMPHONY HEALTH WEEKLY RETAIL PRESCRIPTION DATA RELEASES
`
`Bloomberg Intelligence Symphony Health Weekly Retail Prescription Data Releases
`
`Holiday (Date)
`Christmas (12/25)
`New Year's Day (1/1)
`
`Martin Luther King (1/18)
`
`Good Friday (3/25)
`
`Memorial Day (5/30)
`
`
`
`Release Date
`1/1
`1/8
`1/15
`1/22
`1/29
`2/5
`2/12
`2/19
`2/26
`3/5
`3/12
`3/19
`3/26
`4/2
`4/9
`4/16
`4/23
`4/30
`5/7
`5/14
`5/21
`5/28
`6/4
`6/11
`6/18
`6/25
`7/2
`7/9
`
`Period Start
`12/19/2015
`12/26/2015
`1/2/2016
`1/9/2016
`1/16/2016
`1/23/2016
`1/30/2016
`2/6/2016
`2/13/2016
`2/20/2016
`2/27/2016
`3/5/2016
`3/12/2016
`3/19/2016
`3/26/2016
`4/2/2016
`4/9/2016
`4/16/2016
`4/23/2016
`4/30/2016
`5/7/2016
`5/14/2016
`5/21/2016
`5/28/2016
`6/4/2016
`6/11/2016
`6/18/2016
`6/25/2016
`
`Period End
`12/25/2015
`1/1/2016
`1/8/2016
`1/15/2016
`1/22/2016
`1/29/2016
`2/5/2016
`2/12/2016
`2/19/2016
`2/26/2016
`3/4/2016
`3/11/2016
`3/18/2016
`3/25/2016
`4/1/2016
`4/8/2016
`4/15/2016
`4/22/2016
`4/29/2016
`5/6/2016
`5/13/2016
`5/20/2016
`5/27/2016
`6/3/2016
`6/10/2016
`6/17/2016
`6/24/2016
`7/1/2016
`
`# Business Days*
`6
`6 (Q4) 0 (Q1)
`7
`7
`6
`7
`7
`7
`7
`7
`7
`7
`7
`6
`6 (Q1) 1 (Q2)
`7
`7
`7
`7
`7
`7
`7
`7
`6
`7
`7
`7
`6 (Q2) 1 (Q3)
`
`Q4 15
`
`1Q 16
`
`2Q 16
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 6
`
`

`

`
`
`
`
`
`
`
`
`BI / SYMPHONY HEALTH WEEKLY RETAIL PRESCRIPTION DATA RELEASES
`(CONTINUED)
`
`Bloomberg Intelligence Symphony Health Weekly Retail Prescription Data Releases
`
`Release Date
`
`Period Start
`
`Period End
`
`# Business Days*
`
`Holiday (Date)
`
`7/16
`7/23
`7/30
`8/6
`8/13
`8/20
`8/27
`9/3
`9/10
`9/17
`9/24
`10/1
`10/8
`10/15
`10/22
`10/29
`11/5
`11/12
`11/19
`11/26
`12/3
`12/10
`12/17
`12/24
`12/31
`1/7
`
`7/2/2016
`7/9/2016
`7/16/2016
`7/23/2016
`7/30/2016
`8/6/2016
`8/13/2016
`8/20/2016
`8/27/2016
`9/3/2016
`9/10/2016
`9/17/2016
`9/24/2016
`10/1/2016
`10/8/2016
`10/15/2016
`10/22/2016
`10/29/2016
`11/5/2016
`11/12/2016
`11/19/2016
`11/26/2016
`12/3/2016
`12/10/2016
`12/17/2016
`12/24/2016
`
`7/8/2016
`7/15/2016
`7/22/2016
`7/29/2016
`8/5/2016
`8/12/2016
`8/19/2016
`8/26/2016
`9/2/2016
`9/9/2016
`9/16/2016
`9/23/2016
`9/30/2016
`10/7/2016
`10/14/2016
`10/21/2016
`10/28/2016
`11/4/2016
`11/11/2016
`11/18/2016
`11/25/2016
`12/2/2016
`12/9/2016
`12/16/2016
`12/23/2016
`12/30/2016
`
`6
`7
`7
`7
`7
`7
`7
`7
`7
`6
`7
`7
`7 (Q3)
`7
`7
`7
`7
`7
`7
`7
`6
`7
`7
`7
`7
`6 (Q4)
`
`Independence Day (7/4)
`
`Labor Day (9/5)
`
`Thanksgiving (11/24)
`
`Christmas (12/25)
`
`3Q 16
`
`4Q 16
`
`Weekly Retail Data Available by 8AM NY Time On The Release Date Indicated
`*Calculation of Business days for Retail Channels includes weekends because most retail pharmacies are open on weekends.
`Retail Sales Channels: Prescriptions Dispensed from Brick & Mortar Pharmacies + Mail Order Pharmacies
`
`
`
`
`
`
`
`Return to Table of Contents
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 7
`
`

`

`
`
`
`
`
`
`
`
`BI / SYMPHONY HEALTH MONTHLY RETAIL DATA RELEASES
`
`Bloomberg Intelligence Symphony Health Monthly Retail Data Releases
`Symphony Health Monthly Retail Sales Data Releases
`Release Date
`Month
`# Business Days*
`Holidays
`
`30
`
`29
`
`28
`30
`30
`30
`30
`30
`31
`29
`31
`29
`30
`
`Christmas (12/25)
`
`New Year's Day (1/1)
`Martin Luther King (1/18)
`
`Good Friday (3/25)
`
`Memorial Day (5/30)
`
`Independence Day (7/4)
`
`Labor Day (9/5)
`
`Thanksgiving (11/24)
`Christmas (12/25)
`
`1/12/16
`
`December-15
`
`2/16/16
`
`3/15/16
`4/12/16
`5/17/16
`6/14/16
`7/12/16
`8/16/16
`9/13/16
`10/11/16
`11/15/16
`12/13/16
`1/17/17
`
`January-16
`
`February-16
`March-16
`April-16
`May-16
`June-16
`July-16
`August-16
`September-16
`October-16
`November-16
`December-16
`
`4Q 15
`
`1Q 16
`
`2Q 16
`
`3Q 16
`
`4Q 16
`
`Monthly Retail Data Available 6AM NY Time On The Release Date Indicated
`PHAST IDV MONTHLY RETAIL DATA PUBLISHED ON THE 1ST TUESDAY AFTER THE 2ND SATURDAY OF EACH MONTH
`*Calculation of Business days for Retail Channels includes weekends because most retail pharmacies are open on weekends
`Retail Sales Channels: Brick & Mortar Pharmacies, Mail Order
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 8
`
`

`

`BI / SYMPHONY HEALTH MONTHLY INSTITUTIONAL DATA RELEASES
`
`Monthly Institutional Data Available 6AM NY Time On The Release Date Indicated
`PHAST MONTHLY INSITUTIONAL DATA PUBLISHED ON THE 2ND WEDNESDAY AFTER THE 2ND SATURDAY OF EACH MONTH
`*Calculation of Business days for Institutional Channels excludes weekends because most institutional channels do not stock on weekends.
`Insitutional Sales Channels: Drug Sales into Hospitals, Doctor's Offices, Dialysis Clinics, Long-Term Health Facilities, Prisons
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 9
`
`

`

`
`
`
`
`BI / SYMPHONY HEALTH MONTHLY INTEGRATED DATA RELEASES
`
`Bloomberg Intelligence Symphony Health Monthly Integrated Data Releases
`Symphony Health Monthly Integrated Sales Data Releases
`
`Release Date
`
`Month
`
`# Business Days*
`
`Holidays
`
`Christmas (12/25)
`
`New Year's Day (1/1)
`Martin Luther King (1/18)
`
`Good Friday (3/25)
`
`Memorial Day (5/30)
`
`Independence Day (7/4)
`
`Labor Day (9/5)
`
`Thanksgiving (11/24)
`Christmas (12/25)
`
`
`
`1/25/16
`
`December-15
`
`2/29/16
`
`3/28/16
`4/25/16
`5/30/16
`6/27/16
`7/25/16
`8/29/16
`9/26/16
`10/24/16
`11/28/16
`12/23/16
`1/30/17
`
`January-16
`
`February-16
`March-16
`April-16
`May-16
`June-16
`July-16
`August-16
`September-16
`October-16
`November-16
`December-16
`
`4Q 15
`
`1Q 16
`
`2Q 16
`
`3Q 16
`
`4Q 16
`
`
`
`
`
`
`Monthly Integrated Data Available 6AM NY Time On The Release Date Indicated
`
`
`
`
`
`PHAST IDV MONTHLY INTEGRATED DATA PUBLISHED ON THE 3RD MONDAY AFTER THE 2ND SATURDAY OF EACH MONTH
`
`*Business Days for Integrated Channels Not Calculated as an Aggregate since different drugs have different rates
`
`of distribution through retail or institutional channels.
`
`Integrated Data = Retail Channels + Institutional Channels
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 10
`
`

`

`Bloomberg PHAST IDV
`
`
`Attributes and Metrics
`• Bloomberg PHAST IDV Retail
`• Bloomberg PHAST IDV NonRetail
`• Bloomberg PHAST IDV Integrated
`
`
`
` 1/12/2016
`Symphony Health Solutions
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 11
`
`

`

`DOCUMENT OVERVIEW
`
`This document provides the definitions for the various attributes and metrics that are available in the
`Bloomberg PHAST IDV data for Retail Monthly, Retail Weekly, NonRetail Monthly and Integrated
`Monthly.
`• Attribute:
`• A subject area of interest that can be used for filtering.
`• Attributes define the level of summarization for the display of facts (metrics) within the
`report.
`• For example, Product, Manufacturer, Time, etc.
`
`Bloomberg PHAST IDV Metric and Attributes Summary Table
`
`Metric
`
`Count
`Quantity/Units
`Pack Units
`Packages
`MBS Dollars
`Rx Dollars
`WAC Dollars
`AWP Dollars
`Dimensions/Attributes
`
`Drug
`Physician
`Data Type
`Payment Type
`Time
`
`
`
`
`
`
`Prescription
`X
`X
`X
`
`X
`X
`
`Prescription
`X
`X
`X
`X
`X
`
`
`
`
`
`
`
`
`
`NonRetail
`
`X
`X
`X
`X
`
`X
`X
`NonRetail
`X
`
`Integrated
`
`X
`X
`
`X
`
`X
`X
`Integrated
`X
`
`
`
`
`
`
`
`
`
`
`
`X
`
`X
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 12
`
`

`

`
`
`
`
`
`
`
`
`ATTRIBUTE
`DRUG FORM
`
`DRUG GENERIC NAME
`
`NDC (11)
`
`DRUG PACKAGE SIZE
`
`DRUG NAME
`
`PRODUCT INDICATOR
`
`
`
`DRUG STRENGTH
`
`
`
`
`
`
`
`
`
`
`
`
`
`USC
`
`
`
`
`
`
`
`ATTRIBUTES
`
`An attribute is a category that contains one or more elements. For example, “Product” is an attribute
`and “Lipitor”, “Nexium”, and “Prozac” are all elements of that attribute. Attributes are also known as
`dimensions. These can be described as a person, place or thing.
`
`The table below lists all attributes available in the Bloomberg PHAST IDV modules. They are
`broken out by Attribute Groups, which are logical groups of like attributes. Attributes that are
`specific to a module will be noted as such.
`
`Attribute Groups:
`• Corp Manufacturer Attributes (All Audits)
`• Product Attributes (All Audits)
`• Time Attributes (All Audits)
`• Miscellaneous Attributes (Prescription Audits)
`• Writer Attributes (Prescription Audits)
`Product Attributes
`
`
`
`
`
`EXAMPLE
`Tablet, capsule, liquid, etc.
`
`A sample chemical name is Ibuprofen.
`Advil and Motrin are brand names for
`Ibuprofen.
`
`00071015523 is one of the many NDCs
`for Lipitor
`
`30, 60, 90, etc. (pills in a package)
`
`Lipitor, Nexium, Prozac, etc.
`N: Non-drug item,
`i.e., medical supplies and bulk chemicals
`G: Priced as a Generic drug
`B: Priced as a Brand drug
`
`0.05 MG, 1000 IU, etc.
`
`Example: 32000, second level (USC3)
`contains 3 pertinent digits,
`
`DESCRIPTION
`Describes the appearance or configuration of a drug. The
`long name corresponding to the drug’s form. Depicts the
`drugs dosage form.
`A drug ingredient name adopted by the
`United States Pharmacopoeia Convention (USAN). The
`chemical name is used when a USAN name is not
`available. A product marketed primarily by reference to its
`chemical content rather than by brand name. Generic
`drugs are those prescription products that are no longer
`covered by patents. A generic drug is a copy of an
`existing pharmaceutical compound.
`National Drug Code. A system of codes in which each
`form of a pharmaceutical, as defined by form, strength,
`package size, and representing a brand or generic
`product approved by the FDA, is given a number.
`The quantity of a drug as packaged by the
`Manufacturer or Repacker company. The metric quantity
`used to derive a unit price. It is normally the labeled
`quantity.
`A substance intended for use in the diagnosis, cure,
`treatment, mitigation, or for prevention of disease.
`
`An indicator that will distinguish a product either generic or
`a branded drug
`
`A description of the concentration of the major ingredients
`of the product. Strength is expressed in metrics and is
`also used as an additional descriptor for non-drug items; it
`may contain more than one strength. Represents the
`dosage strength as provided by the manufacturer of the
`specific drug.
`Uniform System of Classification provided by Bluebook.
`Every drug has a USC five-digit code. USC’s can be split
`and new USC groups and relationships can be created.
`First Level (USC2) contains two pertinent digits etc.
`
`
`Return to Table of Contents
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 13
`
`

`

`ATTRIBUTE
`USC DESC
`
`DESCRIPTION
`Bluebook USC 2, 3, 4, or 5 Description
`
`USC 2
`
`USC 3
`USC 4
`
`USC 5
`
`Uniform System of Classification
`Every drug has a USC five-digit code. USCs can be split
`and new USC groups and relationships can be created.
`First Level - Two pertinent digits.
`Second Level - Three pertinent digits.
`Third Level - Four pertinent digits.
`
`
`
`Fourth Level - Five pertinent digits.
`
`
`
`
`
`
`
`EXAMPLE
`USC name, example: Antihyperlipidemic
`Agents
`(Lipitor classification)
`32000: Antihyperlipidemic Agents (Lipitor
`classification)
`
`
`
`32100: Cholesterol Reducers
`32110: HMG-COA Reductase Inhibitors
`32110: HMG-COA Reductase Inhibitors
`(some drugs are only classified to a USC3 or
`USC4 level – Lipitor in this example is
`classified to
`USC4 level.)
`
`ATTRIBUTE
`CORPORATION NAME
`CORPORATION CODE
`MANUFACTURER NAME
`
`
`
`MANUFACTURER CODE
`
`Corporation/Manufacturer Attributes
`
`DESCRIPTION
`An entity made up of one or many manufacturers.
`An entity made up of one or many manufacturers.
`A company that manufactures pharmaceutical products.
`A unique numeric ID for each manufacturer. The
`Manufacturer Code remains constant in the case of a change
`in the Manufacturer naming convention. Internal SHA ID.
`Time Attributes
`
`
`
`EXAMPLE
`Ex: Pfizer, Inc. (Long description)
`Ex: Pfizer, Inc. (Short description)
`Warner-Lambert is a manufacturer within the
`Pfizer corporation.
`
`ATTRIBUTE
`DATA WEEK
`DATA MONTH
`
`Data Week
`Data Month
`
`DESCRIPTION
`
`EXAMPLE
`
`MM/DD/YYYY
`MM/DD/YYYY
`
`Miscellaneous Attributes– Prescription
`
`ATTRIBUTE
`DATA TYPE
`
`DESCRIPTION
`The type of pharmacy or distribution of the prescription.
`
`EXAMPLE
`Retail or Mail Order
`
`Writer Attributes
`– Prescription
`
`ATTRIBUTE
`SPECIALTY CODE
`
`
`
`DESCRIPTION
`An area of medical expertise practiced by a physician, as
`reported by a data agent, broken down into primary and
`secondary specialties.
`
`EXAMPLE
`CD: Cardiovascular diseases
`PCD: Pediatric Cardiology
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 14
`
`

`

`ATTRIBUTE
`PAYMENT TYPE
`
`
`
`
`
`Payer Attributes
`– Prescription
`
`DESCRIPTION
`
`A retail classification that indicates the form of payment for a
`prescription.
`
`EXAMPLE
`
`C = Cash
`M = Medicaid
`X = Medicare
`G = Managed Medicaid A
`= Assistance Programs T
`= Commercial
`
`METRICS
`A metric is a measurement that represents a count, a quantity, a dollar figure. The intent of this
`document is to provide clear, concise definitions for each of the metrics available within the
`associated Bloomberg PHAST IDV data. Examples are given when applicable.
`
`The table below lists all metrics available in the Bloomberg PHAST IDV modules. They are
`broken out by Audit within Metric Groups.
`
`
`
`
`
`
`
`
`
`Standard Metrics
`PRESCRIPTION STANDARD METRICS DESCRIPTION
`NRx COUNT
`The projected number of new prescriptions dispensed for the associated product.
`The cost of projected new prescriptions dispensed for the associated product. This is the dollar
`NRx DOLLARS
`amount that the pharmacy indicates it pays to the wholesaler for the product as related to NRxs.
`Manufacturer’s Benchmark Sales (MBS) is a financial analytic representing the value of
`pharmaceutical product demand. MBS represents a standardized dollar metric based on
`manufacturer’s published catalog or list prices to wholesalers.
`
`DM1 NRx (NRx MBS DOLLARS)
`
`
`
`
`
`
`
`
`
`
`
`NRx MBS Dollars is the standardized dollar metric based on manufacturer’s published catalog or
`list prices to wholesalers for NRxs.
`The projected number of units in the new prescriptions dispensed for the associated product. For
`example, if the NRx Count is 100 new prescriptions and there are 30 tablets included in each new
`prescription, the NRx Qty is 3,000. The quantity figures are a sum of the total NRx quantity
`derived from the dispensed prescriptions.
`The projected number of total prescriptions dispensed for the associated product.
`The cost of projected total prescriptions dispensed for the associated product. This is the dollar
`amount that the pharmacy indicates it pays to the wholesaler for the product as related to TRxs.
`Manufacturer’s Benchmark Sales (MBS) is a financial analytic representing the value of
`pharmaceutical product demand. MBS represents a standardized dollar metric based on
`manufacturer’s published catalog or list prices to wholesalers.
`
`TRx MBS Dollars is the standardized dollar metric based on manufacturer’s published catalog or
`list prices to wholesalers for TRxs.
`The projected number of units in the total prescriptions dispensed for the associated product. For
`example, if the TRx Count is 100 new prescriptions and there are 30 tablets included in each total
`prescription, the TRx Qty is 3,000. The quantity figures are a sum of the total TRx quantity
`derived from the dispensed prescriptions.
`
`
`
`NRx QTY
`
`TRx COUNT
`TRx DOLLARS
`
`DM1 TRx (TRx MBS DOLLARS)
`
`
`
`TRx QTY
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 15
`
`

`

`NONRETAIL STANDARD METRICS
`AWP DOLLARS
`
`DM1 (MBS DOLLARS)
`
`PACK UNITS
`
`VOLUME UNITS
`
`WAC DOLLARS
`
`INTEGRATED STANDARD METRICS
`INTEGRATED AWP DOLLARS
`INTEGRATED MBS DOLLARS
`
`INTEGRATED UNITS
`
`INTEGRATED WAC DOLLARS
`
`DESCRIPTION
`Average Wholesale Price. The AWP Dollars measurement is calculated as the number of
`Packages multiplied by the Package Price as supplied by Medispan.
`Manufacturer’s Benchmark Sales (MBS) is a financial analytic representing the value of
`pharmaceutical product demand. MBS represents a standardized dollar metric based on
`manufacturer’s published catalog or list prices to wholesalers.
`
`
`
`Calculated unit which commonly represents the quantity of an individual level of packaging for a
`specific pharmaceutical product. Non Retail Pack Unit is calculated as (Packages * Package
`Size).
`
`Example – Pack Units is the total number of individual units (e.g. bottles, vials, etc.) distributed in
`non-retail transactions. For example, if a product were normally distributed in a package of six
`bottles, six Pack Units would be listed for one Package.
`The unit of measure that show displacement of space (milliliter, tablet, capsule, etc.) within a
`Pack Unit. For example, if a product were normally distributed in a package of six bottles, and if
`one bottle contains 50 ml, then 300 ml or Volume Units are shipped per one Package. The
`Volume Units measurement is calculated as the number of Pack Units multiplied by the Volume
`of each Pack Unit.
`Wholesale Acquisition Cost. The price the wholesaler pays the manufacturer. The WAC Dollars
`measurement is calculated as the unit price as supplied by Medispan times the number of Pack
`Units times the package size.
`DESCRIPTION
`The combined metrics of Retail AWP dollars and Non-Retail AWP Dollars.
`Manufacturer’s Benchmark Sales (MBS) is a financial analytic representing the value of
`pharmaceutical product demand. MBS represents a standardized dollar metric based on
`manufacturer’s published catalog or list prices to wholesalers.
`The combined metrics of Total Prescription (TRx) Quantity and Non-Retail Volume Units. (Note:
`Units can only be added at the Product/Form level. For example, while a product may have both
`an injectable and a capsule form, adding those units together would not be sensible, so the
`products are broken out into forms for unit addition.)
`The result of converting Retail prescription data into a WAC unit price to then be combined with
`the Non-Retail WAC Unit price.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 16
`
`

`

`DISCLAIMER
`
`The BLOOMBERG PROFESSIONAL® service and BLOOMBERG Data (the “Services”) are owned
`and distributed by Bloomberg Finance L.P. (“BFLP”) in all jurisdictions other than Argentina, Bermuda,
`China, India, Japan, and Korea (the “BLP Countries”). BFLP is a wholly owned subsidiary of
`Bloomberg L.P. (“BLP”). BLP provides BFLP with global marketing and operational support and
`service for the Services and distributes the Services either directly or through a non-BFLP subsidiary
`in the BLP Countries. Certain functionalities distributed via the Services are available only to
`sophisticated institutional investors and only where the necessary legal clearance has been obtained.
`BFLP, BLP and their affiliates do not guarantee the accuracy of prices or information in the Services.
`Nothing in the Services shall constitute or be construed as an offering of financial instruments by
`BFLP, BLP or their affiliates, or as investment advice or recommendations by BFLP, BLP or their
`affiliates of “an investment strategy or whether or not to “buy”, “sell” or “hold” an investment.
`Information available via the Services should not be considered as information sufficient upon which
`to base an investment decision. BLOOMBERG, BLOOMBERG PROFESSIONAL, BLOOMBERG
`MARKETS, BLOOMBERG NEWS, BLOOMBERG ANYWHERE, BLOOMBERG TRADEBOOK,
`BLOOMBERG TELEVISION, BLOOMBERG RADIO, BLOOMBERG PRESS and BLOOMBERG.COM
`are trademarks and service marks of BFLP, a Delaware limited partnership, or its subsidiaries.
`©2016 Bloomberg Finance L.P. All rights reserved. This document and its contents may not be
`forwarded or redistributed without the prior consent of Bloomberg.
`
`Bloomberg Intelligence is a service provided by Bloomberg Finance L.P. and its affiliates. Bloomberg
`Intelligence shall not constitute, nor be construed as, investment advice or investment
`recommendations (i.e., recommendations as to whether or not to “buy”, “sell”, “hold”, or to enter or not
`to enter into any other transaction involving any specific interest) or a recommendation as to an
`investment or other strategy. No aspect of the Bloomberg Intelligence function is based on the
`consideration of a customer's individual circumstances. Bloomberg Intelligence should not be
`considered as information sufficient upon which to base an investment decision. You should
`determine on your own whether you agree with Bloomberg Intelligence.
`
`Bloomberg Intelligence is offered where the necessary legal clearances have been obtained.
`Bloomberg Intelligence should not be construed as tax or accounting advice or as a service designed
`to facilitate any Bloomberg Intelligence subscriber's compliance with its tax, accounting, or other legal
`obligations. Employees involved in Bloomberg Intelligence may hold positions in the securities
`analyzed or discussed on Bloomberg Intelligence.
`
`
`
`
`
`
`
`Return to Table of Contents
`
`
`
`
`
`Opiant Exhibit 2197
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00694
`Page 17
`
`